search
Back to results

Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

Primary Purpose

Alzheimer Disease

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Simvastatin
Sponsored by
National Institute on Aging (NIA)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer Disease focused on measuring Cholesterol-lowering drug, Mild to Moderate Alzheimer disease

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Mild to moderate patients with AD who are free of life-threatening disease and who do not require lipid-lowering treatment according to current guidelines. NINCDS/ADRDA criteria for probable AD. Mini-Mental-State-Exam (MMSE) score between 12 and 26. Stable medical condition for 3 months prior to the screening visit. Age greater than or equal to 50 years, and no upper age limit. Lives in a community dwelling, not in a nursing home. Stable doses of (non-excluded) medications with central nervous system activity for 4 weeks prior to the screening visit. Physical condition acceptable for the study as confirmed by medical history, physical exam, neurologic exam and clinical laboratory tests. Informant/study partner available and willing to accompany participant to all scheduled visits and complete informant-based assessments and to supervise administration of study medications. Fluent in English or Spanish. Modified Hachinski is less than or equal to 4. Exclusion criteria: Coronary heart disease (CHD) including angina, or peripheral vascular disease including symptomatic carotid artery disease, or stroke or TIA, as these individuals are likely to require treatment with lipid-lowering drugs. Serious renal disease. Uncontrolled diabetes. Triglycerides are greater than 500 mg/dL. LDL-Cholesterol below 80 mg/dL Upper limit for the National Cholesterol Education Program (NCEP) guidelines for LDL-Cholesterol is 130-190 mg/dL, depending on age and other cardiovascular risk factors. Other indication for the need to treat with lipid-lowering drug. Active liver disease or persistent elevation in serum transaminase. Active neoplastic disease (skin tumors other than melanoma are not exclusionary; subjects with stable prostate cancer may be included at the discretion of the Project Director). Use of another investigational agent within 2 months of the screening visit. History of clinically significant stroke. Current evidence or history in the past 2 years of seizures, head injury with loss of consciousness and/or immediate confusion after the injury. Current DSM-IV criteria based diagnosis for major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse. Blindness, deafness, language difficulties or any other disability which may prevent the subject from participating or cooperating in the protocol.

Sites / Locations

  • University of Alabama, Birmingham
  • Barrow Neurology Group
  • Arizona Health Sciences Center, University of Arizona
  • University of California, Irvine
  • University of California, San Diego
  • University of Southern California
  • University of California, Los Angeles
  • Stanford University/VA Aging Clinical Research Center
  • University of California, Davis
  • Yale University School of Medicine
  • Georgetown University, Memory Disorder Program
  • Howard University
  • Baumel Eisner Neuromedical Institute
  • Mayo Clinic (Jacksonville)
  • Wein Center
  • Emory University
  • Northwestern University
  • Rush Alzheimer's Disease Center, Rush University
  • Indiana University Alzheimer's Center
  • University of Kentucky, Sanders-Brown Center on Aging
  • Brigham and Women's Hospital
  • Boston University School of Medicine
  • University of Michigan at Ann Arbor
  • Mayo Clinic
  • St. Louis University
  • Washington University, St. Louis School of Medicine
  • SUNY Downstate
  • New York University School Of Medicine
  • Mount Sinai School of Medicine
  • Columbia University
  • University of Rochester Medical Center
  • SUNY Stony Brook
  • Neurological Care of NY
  • Duke University Medical Center
  • University Memory and Aging Center, Case Western Reserve University/University Hospitals of Cleveland
  • Oregon Health and Sciences University
  • University of Pennsylvania School of Medicine, Alzheimer's Disease Center
  • University of Pittsburgh
  • Brown University-Memorial Hospital of Rhode Island
  • Medical University of South Carolina
  • University of Texas, Southwestern Medical School
  • Baylor College of Medicine, Alzheimer's Disease Research Center
  • Southwestern Vermont Medical Center
  • University of Washington at Seattle

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
February 3, 2003
Last Updated
July 24, 2009
Sponsor
National Institute on Aging (NIA)
Collaborators
Alzheimer's Disease Cooperative Study (ADCS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00053599
Brief Title
Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study
Official Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
June 2009
Overall Recruitment Status
Completed
Study Start Date
December 2002 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
October 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute on Aging (NIA)
Collaborators
Alzheimer's Disease Cooperative Study (ADCS)

4. Oversight

5. Study Description

Brief Summary
CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly used to treat high cholesterol levels, which increase the risk of heart disease and stroke.
Detailed Description
In earlier studies in animals and humans, researchers found that lowering cholesterol levels with statins seems to have a positive impact on brain function and reduces the risk of AD. The CLASP trial will test the link between using a cholesterol lowering medication and slowing disease progress in people with mild to moderate Alzheimer's disease (AD). CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of AD. The clinical trial will include the treatment of patients with mild to moderate AD, and the objective is to evaluate the safety and efficacy of simvastatin to slow the progression of AD, as measured by the cognitive portion of the AD Assessment Scale. Measures of clinical global change (ADCS-CGIC), mental status, functional ability, behavioral disturbances, quality of life and economic indicators will be made also. The study design is randomized, double-blind, placebo-controlled, parallel group design with equal randomization to drug and placebo. Randomization will be stratified and blocked to ensure balanced assignment within site. Sample size will include 400 participants enrolled from approximately 40 sites with a goal of 10 to 15 volunteers enrolled at each site. Study medication will be as follows: 20 mg of simvastatin or matching placebo to be given for 6 weeks, followed by 40 mg of simvastatin or matching placebo for the remainder of the 18-month study period. Participants will be instructed to take the medication once a day in the evening. Safety parameters to be checked will include adverse events, symptom checklists, vital signs, physical and neurological examinations, and laboratory tests.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
Cholesterol-lowering drug, Mild to Moderate Alzheimer disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
400 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Simvastatin

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Mild to moderate patients with AD who are free of life-threatening disease and who do not require lipid-lowering treatment according to current guidelines. NINCDS/ADRDA criteria for probable AD. Mini-Mental-State-Exam (MMSE) score between 12 and 26. Stable medical condition for 3 months prior to the screening visit. Age greater than or equal to 50 years, and no upper age limit. Lives in a community dwelling, not in a nursing home. Stable doses of (non-excluded) medications with central nervous system activity for 4 weeks prior to the screening visit. Physical condition acceptable for the study as confirmed by medical history, physical exam, neurologic exam and clinical laboratory tests. Informant/study partner available and willing to accompany participant to all scheduled visits and complete informant-based assessments and to supervise administration of study medications. Fluent in English or Spanish. Modified Hachinski is less than or equal to 4. Exclusion criteria: Coronary heart disease (CHD) including angina, or peripheral vascular disease including symptomatic carotid artery disease, or stroke or TIA, as these individuals are likely to require treatment with lipid-lowering drugs. Serious renal disease. Uncontrolled diabetes. Triglycerides are greater than 500 mg/dL. LDL-Cholesterol below 80 mg/dL Upper limit for the National Cholesterol Education Program (NCEP) guidelines for LDL-Cholesterol is 130-190 mg/dL, depending on age and other cardiovascular risk factors. Other indication for the need to treat with lipid-lowering drug. Active liver disease or persistent elevation in serum transaminase. Active neoplastic disease (skin tumors other than melanoma are not exclusionary; subjects with stable prostate cancer may be included at the discretion of the Project Director). Use of another investigational agent within 2 months of the screening visit. History of clinically significant stroke. Current evidence or history in the past 2 years of seizures, head injury with loss of consciousness and/or immediate confusion after the injury. Current DSM-IV criteria based diagnosis for major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse. Blindness, deafness, language difficulties or any other disability which may prevent the subject from participating or cooperating in the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mary Sano, PhD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Leon J. Thal, MD
Organizational Affiliation
University of California, San Diego
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama, Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294-0017
Country
United States
Facility Name
Barrow Neurology Group
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
Arizona Health Sciences Center, University of Arizona
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724-5023
Country
United States
Facility Name
University of California, Irvine
City
Irvine
State/Province
California
ZIP/Postal Code
92697-7016
Country
United States
Facility Name
University of California, San Diego
City
La Jolla
State/Province
California
ZIP/Postal Code
92093-0948
Country
United States
Facility Name
University of Southern California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90093
Country
United States
Facility Name
University of California, Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Stanford University/VA Aging Clinical Research Center
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
University of California, Davis
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
Yale University School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Facility Name
Georgetown University, Memory Disorder Program
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20057
Country
United States
Facility Name
Howard University
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20060
Country
United States
Facility Name
Baumel Eisner Neuromedical Institute
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Facility Name
Mayo Clinic (Jacksonville)
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Wein Center
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30329
Country
United States
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Rush Alzheimer's Disease Center, Rush University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Indiana University Alzheimer's Center
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
University of Kentucky, Sanders-Brown Center on Aging
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536-0230
Country
United States
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Boston University School of Medicine
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
University of Michigan at Ann Arbor
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109-0504
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55901
Country
United States
Facility Name
St. Louis University
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63104
Country
United States
Facility Name
Washington University, St. Louis School of Medicine
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63108
Country
United States
Facility Name
SUNY Downstate
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11203
Country
United States
Facility Name
New York University School Of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Mount Sinai School of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
University of Rochester Medical Center
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
SUNY Stony Brook
City
Stonybrook
State/Province
New York
ZIP/Postal Code
11794-8121
Country
United States
Facility Name
Neurological Care of NY
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Facility Name
University Memory and Aging Center, Case Western Reserve University/University Hospitals of Cleveland
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44120
Country
United States
Facility Name
Oregon Health and Sciences University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97201
Country
United States
Facility Name
University of Pennsylvania School of Medicine, Alzheimer's Disease Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Brown University-Memorial Hospital of Rhode Island
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Facility Name
Medical University of South Carolina
City
North Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
University of Texas, Southwestern Medical School
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
Baylor College of Medicine, Alzheimer's Disease Research Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Southwestern Vermont Medical Center
City
Bennington
State/Province
Vermont
ZIP/Postal Code
05201
Country
United States
Facility Name
University of Washington at Seattle
City
Seattle
State/Province
Washington
ZIP/Postal Code
98108
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11881745
Citation
Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci. 2001 Nov;24(11 Suppl):S45-8. doi: 10.1016/s0166-2236(00)01990-1.
Results Reference
background
PubMed Identifier
11089820
Citation
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000 Nov 11;356(9242):1627-31. doi: 10.1016/s0140-6736(00)03155-x. Erratum In: Lancet 2001 Feb 17;357(9255):562.
Results Reference
background
PubMed Identifier
12205648
Citation
Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002 Sep;52(3):346-50. doi: 10.1002/ana.10292.
Results Reference
background
Links:
URL
http://www.adcs.org/
Description
Alzheimer's Disease Cooperative Study

Learn more about this trial

Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

We'll reach out to this number within 24 hrs